Abide doses first patient in Phase Ib trial of ABX-1431 to treat tourette syndrome

US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news